Inozyme Pharma (INZY) Stock Price, News & Analysis

Company Overview

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $4.00 to $4.00
• 50-Day Range: $3.95 to $4.00
• 52-Week Range: $0.72 to $6.24
• Volume: N/A
• Average Volume: 960,267 shs
• Market Capitalization: $258.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.75
• Consensus Rating: Hold

Inozyme Pharma Stock Analysis - MarketRank™

Inozyme Pharma scored higher than 29% of companies evaluated by MarketBeat, and ranked 820th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Inozyme Pharma has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Inozyme Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.59) to ($1.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inozyme Pharma is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inozyme Pharma is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inozyme Pharma has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for INZY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inozyme Pharma does not currently pay a dividend.

Dividend Growth

Inozyme Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for INZY.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for INZY on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inozyme Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.18% of the stock of Inozyme Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.30% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INZY Stock Analysis - Frequently Asked Questions

How were Inozyme Pharma's earnings last quarter?

Inozyme Pharma, Inc. (NASDAQ:INZY) released its earnings results on Wednesday, May, 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.01.

When did Inozyme Pharma IPO?

Inozyme Pharma (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Inozyme Pharma's major shareholders?

Inozyme Pharma's top institutional investors include Beryl Capital Management LLC (9.79%), Alpine Associates Management Inc. (3.39%), Affinity Asset Advisors LLC (2.71%) and Gabelli Funds LLC (2.26%). Insiders that own company stock include Robert Lorne Hopfner, Pivotal Bioventure Partners Fu, Henric Bjorn Bjarke and Douglas A Treco.
View institutional ownership trends.

What other stocks do shareholders of Inozyme Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inozyme Pharma investors own include Salesforce (CRM), Home Depot (HD), Chevron (CVX), CocaCola (KO), Meta Platforms (META), QUALCOMM (QCOM) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 9/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INZY
• CIK: 1693011
• Web: www.inozyme.com
• Phone: 857-330-4340
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Inozyme Pharma: $11.75
• High Price Target: $23.00
• Low Price Target: $4.00
• Potential Upside/Downside: +193.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.44
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$102.02 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -159.93%
• Return on Assets: -82.48%

Debt

• Debt-to-Equity Ratio: 0.65
• Current Ratio: 2.19
• Quick Ratio: 2.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.90 per share
• Price / Book: 4.44

Miscellaneous

• Outstanding Shares: 64,562,000
• Free Float: 56,698,000
• Market Cap: $258.25 million
• Optionable: Optionable
• Beta: 2.27